The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-12-06
DOI
10.3389/fonc.2019.01366
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
- (2019) Yuna Blum et al. Nature Communications
- Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays
- (2019) David B. Chapel et al. HUMAN PATHOLOGY
- NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy
- (2019) Rosa Sottile et al. INTERNATIONAL JOURNAL OF CANCER
- A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
- (2019) Emilie M. J. van Brummelen et al. INVESTIGATIONAL NEW DRUGS
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
- (2019) Giorgio V Scagliotti et al. Lancet Respiratory Medicine
- Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion
- (2019) Pietro Bertino et al. OncoImmunology
- LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
- (2019) S Popat et al. ANNALS OF ONCOLOGY
- Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group
- (2018) Aliya Noor Husain et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients
- (2018) Swati Khanna et al. CLINICAL CANCER RESEARCH
- Metabolic Barriers to T Cell Function in Tumors
- (2018) Ayaka Sugiura et al. JOURNAL OF IMMUNOLOGY
- Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma
- (2018) Namrata S. Patil et al. Journal of Thoracic Oncology
- How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations
- (2018) Hubert Rehrauer et al. ONCOGENE
- Introducing the new BTS guideline: the investigation and management of pleural malignant mesothelioma
- (2018) Ian Woolhouse et al. THORAX
- Targeting Tie-2/angiopoietin axis in experimental mesothelioma confers differential responses and raises predictive implications
- (2018) Sophia Magkouta et al. Oncotarget
- Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
- (2018) Takuya Watanabe et al. Oncotarget
- Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization
- (2018) Annalisa Bosi et al. Journal of Immunology Research
- Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma
- (2018) Myung-Chul Kim et al. BMC CANCER
- Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM).
- (2018) Arpita Desai et al. JOURNAL OF CLINICAL ONCOLOGY
- Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
- (2018) Yannis Metaxas et al. Journal of Thoracic Oncology
- Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo
- (2018) Chang Li et al. Scientific Reports
- Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
- (2018) Xian Shen et al. BMJ-British Medical Journal
- VISTA expressed in tumour cells regulates T cell function
- (2018) Kumuluzi Mulati et al. BRITISH JOURNAL OF CANCER
- Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
- (2018) Judith Feucht et al. NATURE MEDICINE
- Turning foes to friends: targeting cancer-associated fibroblasts
- (2018) Xueman Chen et al. NATURE REVIEWS DRUG DISCOVERY
- Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types
- (2018) Marcella Tazzari et al. Journal of Immunology Research
- Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
- (2018) Aaron S. Mansfield et al. Journal of Thoracic Oncology
- P2.06-026 A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma - Trial in Progress
- (2017) Wei-Sen Lam et al. Journal of Thoracic Oncology
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
- (2017) Michele Maio et al. LANCET ONCOLOGY
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
- (2017) Evan W Alley et al. LANCET ONCOLOGY
- Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
- (2017) Elly Marcq et al. Oncotarget
- The “don't eat me” signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma
- (2017) Christian M. Schürch et al. OncoImmunology
- Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma
- (2017) Kazuma Kiyotani et al. OncoImmunology
- c-Met expression and MET amplification in malignant pleural mesothelioma
- (2016) Melanie C. Bois et al. Annals of Diagnostic Pathology
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions
- (2016) Rajesh Thomas et al. CHEST
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages
- (2016) Anne-Laure Chéné et al. Journal of Thoracic Oncology
- Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression
- (2016) Lysanne A. Lievense et al. Journal of Thoracic Oncology
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- (2016) Raphael Bueno et al. NATURE GENETICS
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
- (2016) Vincenzo Bronte et al. Nature Communications
- Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
- (2016) M. M. Awad et al. Cancer Immunology Research
- Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma
- (2016) Abdullah Cetin Tanrikulu et al. Environmental Health and Preventive Medicine
- Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma
- (2016) Elly Marcq et al. OncoImmunology
- PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
- (2016) Rajani Kanteti et al. Scientific Reports
- Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales
- (2015) P. Beckett et al. LUNG CANCER
- Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT
- (2015) Roslyn J. Francis et al. LUNG CANCER
- Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
- (2015) Atsushi Mitsuhashi et al. Nature Communications
- The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
- (2015) Hideki Ujiie et al. OncoImmunology
- Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
- (2015) Susana Cedrés et al. PLoS One
- Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma
- (2015) Iris Chiara Salaroglio et al. Oncotarget
- Fibroblast Growth Factor Receptor Inhibition Is Active against Mesothelioma and Synergizes with Radio- and Chemotherapy
- (2014) Karin Schelch et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
- (2014) Robin Cornelissen et al. PLoS One
- Increased Levels of C-C Chemokine RANTES in Asbestos Exposed Workers and in Malignant Mesothelioma Patients from an Hyperendemic Area
- (2014) Manola Comar et al. PLoS One
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation
- (2014) M Cioce et al. Cell Death & Disease
- Comparative Immunohistochemical Analysis of IMP3, GLUT1, EMA, CD146, and Desmin for Distinguishing Malignant Mesothelioma From Reactive Mesothelial Cells
- (2013) Hiroshi Minato et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Malignant Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is GLUT1 Expression a Major Prognostic Factor? A Preliminary Study
- (2013) J. Hommell-Fontaine et al. ANNALS OF SURGICAL ONCOLOGY
- Defect in recruiting effector memory CD8+T-cells in malignant pleural effusions compared to normal pleural fluid
- (2013) Arnaud Scherpereel et al. BMC CANCER
- Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
- (2013) Petra C Schuberth et al. Journal of Translational Medicine
- NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation
- (2012) Paola Vacca et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase
- (2012) Connie Jackaman et al. INTERNATIONAL IMMUNOLOGY
- TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth
- (2012) Makiko Fujii et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions
- (2012) Christophe Blanquart et al. Journal of Thoracic Oncology
- Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network
- (2011) Qi Li et al. AMERICAN JOURNAL OF PATHOLOGY
- Identification of Novel Markers for the Diagnosis of Malignant Pleural Mesothelioma
- (2011) Fabien Gueugnon et al. AMERICAN JOURNAL OF PATHOLOGY
- Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma
- (2011) Bryan M. Burt et al. CANCER
- Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
- (2011) E. K. Moon et al. CLINICAL CANCER RESEARCH
- Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)
- (2011) Thierry Jahan et al. LUNG CANCER
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells
- (2011) S. Amarnath et al. Science Translational Medicine
- CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
- (2010) Noriyuki Yamada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Macrophage Expression of Hypoxia-Inducible Factor-1 Suppresses T-Cell Function and Promotes Tumor Progression
- (2010) A. L. Doedens et al. CANCER RESEARCH
- Transforming growth factor-beta 1 (TGF-β1)- and β2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer
- (2010) J. MAEDA et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic Therapy
- (2010) S. C. H. Kao et al. CLINICAL CANCER RESEARCH
- HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
- (2010) Cesar A. Corzo et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma
- (2010) Tong Li et al. JOURNAL OF PATHOLOGY
- Asbestos, carbon nanotubes and the pleural mesothelium: a review and the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma
- (2010) Ken Donaldson et al. Particle and Fibre Toxicology
- Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation
- (2010) Haining Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?☆
- (2010) Marco Lucchi et al. Interactive Cardiovascular and Thoracic Surgery
- Clinical Impact and Reliability of Pleural Fluid Mesothelin in Undiagnosed Pleural Effusions
- (2009) Helen E. Davies et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells
- (2009) C. Jackaman et al. EUROPEAN RESPIRATORY JOURNAL
- Tryptase Mast Cells in Malignant Pleural Mesothelioma as an Independent Favorable Prognostic Factor
- (2009) Greta Alì et al. Journal of Thoracic Oncology
- Global Gene Expression Profiling Of Human Pleural Mesotheliomas: Identification of Matrix Metalloproteinase 14 (MMP-14) as Potential Tumour Target
- (2009) Stefania Crispi et al. PLoS One
- Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma
- (2008) Masaki Anraku et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma
- (2008) N. R. Miselis et al. MOLECULAR CANCER THERAPEUTICS
- EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors
- (2007) H Kothmaier et al. THORAX
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started